Novel monodisperse FePt nanocomposites for T2-weighted magnetic resonance imaging: biomedical theranostics applications.
Zhi-Xuan ChangChien-Hsiu LiMichael HsiaoChi-Ying F HuangMing-Hsien ChanMichael HsiaoPublished in: Nanoscale advances (2021)
Given the high incidence and mortality of cancer, current research is focused on designing efficient diagnostic methods. At present, clinical diagnoses are made based on X-ray, computed tomography, magnetic resonance imaging (MRI), ultrasound, and fiber optic endoscopy. MRI is a powerful diagnostic tool because it is non-invasive, has a high spatial resolution, uses non-ionizing radiation, and has good soft-tissue contrast. However, the long relaxation time of water protons may result in the inability to distinguish different tissues. To overcome this drawback of MRI, magnetic resonance contrast agents can enhance the contrast, improve the sensitivity of MRI-based diagnoses, increase the success rate of surgery, and reduce tumor recurrence. This review focuses on using iron-platinum (FePt) nanoparticles (NPs) in T2-weighted MRI to detect tumor location based on dark-field changes. In addition, existing methods for optimizing and improving FePt NPs are reviewed, and the MRI applications of FePt NPs are discussed. FePT NPs are expected to strengthen MRI resolution, thereby helping to inhibit tumor development.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- diffusion weighted imaging
- dual energy
- type diabetes
- soft tissue
- gene expression
- high resolution
- optical coherence tomography
- percutaneous coronary intervention
- atrial fibrillation
- positron emission tomography
- squamous cell carcinoma
- single molecule
- risk factors
- cardiovascular disease